Yissum

Yissum
Name	Yissum
Formation	1964
Headquarters	Jerusalem
Location	Israel
Parent organization	Hebrew University of Jerusalem
Type	Technology transfer company

Yissum is the technology transfer company associated with the Hebrew University of Jerusalem that commercializes academic intellectual property, manages patents, and incubates start-up companies. Founded in 1964, it serves as an interface among inventors, investors, multinational corporations, and the Israeli innovation ecosystem, supporting translational research from laboratories to markets. Yissum has been linked to a wide array of technologies spanning biotechnology, pharmaceuticals, cleantech, agricultural technology, materials science, and information technology.

History

Yissum was established in 1964 at the Hebrew University of Jerusalem to formalize commercialization pathways similar to practices at Stanford University, Massachusetts Institute of Technology, and University of California. Early collaborations connected researchers at the Faculty of Agriculture, Food and Environment and the Faculty of Medicine with industry partners including Teva Pharmaceutical Industries, DuPont, and Monsanto. Throughout the 1970s and 1980s Yissum expanded patenting and licensing activity, engaging with multinational firms such as Pfizer, Roche, Bayer, and Johnson & Johnson. The 1990s and 2000s saw growth in biotechnology spin-offs and venture capital links with firms and investors like Sequoia Capital, Israel Biotech Fund, Groupe Sanofi, and Intel. In the 2010s Yissum played a role in Israeli high-tech growth alongside institutions such as Technion – Israel Institute of Technology, Weizmann Institute of Science, and incubators like Yozma. Yissum's trajectory parallels global trends exemplified by entities at Harvard University, Columbia University, and University of Cambridge.

Mission and Activities

Yissum's mission includes protection of intellectual property, licensing, startup formation, and commercialization strategies for technologies developed at the Hebrew University of Jerusalem, including fields linked to the Faculty of Natural Sciences, Faculty of Social Sciences, and affiliated research centers. Yissum negotiates agreements with corporations including GlaxoSmithKline, Novartis, Apple Inc., and Google for technology transfer, while supporting entrepreneurs via partnerships with accelerators like MassChallenge, Techstars, and local incubators such as Jerusalem Venture Partners. Activities encompass patent prosecution in jurisdictions aligned with the World Intellectual Property Organization standards, management of equity in spin-offs, and collaboration with funding sources including Israel Innovation Authority, European Research Council, and private venture capital firms like Benchmark Capital.

Technology Transfer and Commercialization

Yissum operates licensing programs that connect university inventors to licensees across sectors such as pharmaceuticals, agritech, cleantech, and information technology. It has executed licensing deals with companies like Merck & Co., Bristol-Myers Squibb, Caterpillar Inc., and Siemens. Yissum supports translational projects through proof-of-concept funding, joint development agreements with corporations like BASF and 3M, and collaboration with government initiatives such as those run by Ministry of Science and Technology (Israel). The company engages with international markets via offices and partners in regions including North America, Europe, and Asia, negotiating patents under regimes influenced by the Patent Cooperation Treaty and bilateral agreements with countries such as United States, Germany, and China.

Research and Innovations

Technologies handled by Yissum span immunotherapy, gene editing, drug delivery, cannabis-derived therapeutics, precision agriculture, and materials engineering. Innovations originate from laboratories of researchers affiliated with the Hebrew University of Jerusalem including scientists from the Institute of Life Sciences, Manna Center Program in Food Safety and Security, and the Israel Institute for Biological Research collaborations. Notable research areas include monoclonal antibodies, recombinant proteins, CRISPR-related methods, nanotechnology, sensor technologies, and computational biology, often intersecting with institutions such as Broad Institute, Cold Spring Harbor Laboratory, and European Molecular Biology Laboratory.

Spin-offs and Notable Products

Yissum has been instrumental in creating numerous startups and products that reached markets through partners such as TEVA Pharmaceutical Industries, Medtronic, and Pfizer. Spin-offs have included companies working on oncology therapeutics, agricultural seeds, water desalination technologies, diagnostics, and consumer products. Several enterprises have attracted investment from international venture capital firms including Kleiner Perkins, Accel Partners, and strategic corporate investors like Johnson & Johnson Innovation. Licensed products reached distribution channels operated by conglomerates such as Unilever and Nestlé.

Governance and Funding

Yissum is governed by a board of directors linked to the Hebrew University of Jerusalem and composed of academic leaders, business executives, and legal experts with ties to entities like Israel Innovation Authority, European Investment Bank, and major philanthropic organizations such as Howard Hughes Medical Institute and Gates Foundation. Funding sources include licensing revenue, equity stakes in startups, grants from bodies like the European Commission (Horizon programs), translational funds from the Israel Science Foundation, and private investment from venture capital firms and angel investors. Financial oversight follows practices observed at technology transfer offices of Yale University, University of Oxford, and Imperial College London.

Controversies and Criticism

Yissum has faced criticism similar to other university tech transfer offices regarding conflict of interest, allocation of royalty streams, and balance between academic openness and commercial secrecy, debates paralleled at institutions such as Columbia University, Johns Hopkins University, and University of California. Critics include academic groups and policy advocates aligned with organizations like Open Science Federation and think tanks focused on intellectual property reform. Regulatory scrutiny has involved issues tied to patent enforcement strategies, licensing exclusivity, and relations with pharmaceutical firms during public health debates involving entities such as World Health Organization and national health ministries.

Category:Technology transfer organizations